Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.

被引：0

作者：

Fountzilas, Christos

Liao, Chih-Yi

Pelster, Meredith

Li, Daneng

Deming, Dustin A.

Sahai, Vaibhav

Kankeu Fonkoua, Lionel Aurelien

Cohn, Allen Lee

Mantry, Parvez

Richards, Donald A.

Kingsley, Ed

Wu, Frank

Peng, Peng

Hennessy, Katie

Wang, Hui

Shan, Yujun

Sun, Caixia

Fan, Jean

Javle, Milind M.

Mahipal, Amit

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[2] Univ Chicago, Med Ctr, Chicago, IL USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA

[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[6] Univ Michigan, Ann Arbor, MI USA

[7] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA

[8] Rocky Mt Canc Ctr, Denver, CO USA

[9] Liver Inst Methodist Dallas, Dallas, TX USA

[10] Texas Oncol Tyler, Tyler, TX USA

[11] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[12] TransThera Sci Nanjing Inc, Nanjing, Peoples R China

[13] TransThera Sci US Inc, Gaithersburg, MD USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[15] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland Hts, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.608

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

608

引用

页码：608 / 608

页数：1

共 50 条

[1] Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
Javle, Milind M.
Mahipal, Amit
Fonkoua, Lionel Aurelien Kankeu
Fountzilas, Christos
Li, Daneng
Pelster, Meredith
Liao, Chih-Yi
Richards, Donald A.
Deming, Dustin A.
Younes, Mohamad Ahmad
Mantry, Parvez
Cohn, Allen Lee
Kingsley, Ed
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Shan, Yujun
Wu, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 434 - 434
[2] Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.
Sun, Yan
Shi, Yuankai
Zhang, Li
Liu, Xiaoqing
Zhou, Caicun
Zhang, Li
Wang, Dong
Li, Qiang
Zhang, Shucai
Qin, Shukui
Hu, Chunhong
Zhang, Yiping
Chen, Jianhua
Song, Yong
Feng, Ji Feng
Cheng, Ying
Zhang, Helong
Wu, Yi Long
Xu, Nong
Zhou, Jianying
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] FINAL OVERALL SURVIVAL AND UPDATED BIOMARKER ANALYSIS RESULTS FROM THE RANDOMIZED PHASE III ICOGEN TRIAL
Yan, S.
Yuankai, S.
Li, Z.
Xiaoqing, L.
Zhou, C.
Li, Z.
Dong, W.
Qiang, L.
Qin, S.
Shucai, Z.
ANNALS OF ONCOLOGY, 2012, 23 : 416 - 416
[4] Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Zhu, Andrew X.
Macarulla, Teresa
Javle, Milind M.
Kelley, R. Kate
Lubner, Sam J.
Adeva, Jorge
Cleary, James M.
Catenacci, Daniel V. T.
Borad, Mitesh J.
Bridgewater, John A.
Harris, William P.
Murphy, Adrian G.
Oh, Do-Youn
Whisenant, Jonathan R.
Lowery, Maeve A.
Goyal, Lipika
Shroff, Rachna T.
El-Khoueiry, Anthony B.
Chamberlain, Christina X.
Aguado-Fraile, Elia
Choe, Sung
Wu, Bin
Liu, Hua
Gliser, Camelia
Pandya, Shuchi S.
Valle, Juan W.
Abou-Alfa, Ghassan K.
JAMA ONCOLOGY, 2021, 7 (11) : 1669 - 1677
[5] Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
Javle, Milind M.
Fountzilas, Christos
Li, Daneng
Fonkoua, Lionel Aurelien Kankeu
Fan, Jean
Peng, Peng
Wang, Hui
Ngo, Brenda
Sun, Caixia
Ru, Qinhua Cindy
Wu, Frank
Mahipal, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 539 - 539
[6] A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma
Goyal, Lipika
Zheng, Hui
Yurgelun, Matthew B.
Abrams, Thomas A.
Allen, Jill N.
Cleary, James M.
Knowles, Michelle
Regan, Eileen
Reardon, Amanda
Khachatryan, Anna
Jain, Rakesh K.
Nardi, Valentina
Borger, Darrell R.
Duda, Dan G.
Zhu, Andrew X.
CANCER, 2017, 123 (11) : 1979 - 1988
[7] Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
Lu, Shun
Zhang, Yiping
Zhang, Guojun
Zhou, Jianying
Cang, Shundong
Cheng, Ying
Wu, Gang
Cao, Peiguo
Lv, Dongqing
Jian, Hong
Jin, Xiangming
Chen, Chengshui
Tian, Panwen
Wang, Kai
Jiang, Guanming
Chen, Gongyan
Chen, Qun
Zhao, Hui
Ding, Cuimin
Guo, Renhua
Sun, Guoping
Wang, Bin
Jiang, Liyan
Liu, Zhe
Fang, Jian
Yang, Junquan
Zhuang, Wu
Liu, Yunpeng
Zhang, Jian
Pan, Yueyin
Chen, Jun
Yu, Qitao
Zhao, Min
Cui, Jiuwei
Li, Dianming
Yi, Tienan
Yu, Zhuang
Yang, Yan
Zhang, Yan
Zhi, Xiuyi
Huang, Yunchao
Wu, Rong
Chen, Liangan
Zang, Aimin
Cao, Lejie
Li, Qingshan
Li, Xiaoling
Song, Yong
Wang, Donglin
Zhang, Shucai
LUNG CANCER, 2024, 195
[8] Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.
Ma, Fei
Li, Qiao
Guan, Xiuwen
Chen, Shanshan
Yi, Zongbi
Lan, Bo
Xing, Puyuan
Fan, Ying
Wang, Jiayu
Luo, Yang
Yuan, Peng
Cai, Ruigang
Zhang, Pin
Li, Qing
Xu, Binghe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial
Zhao, Hua
Wang, Yang
Yu, Jinpu
Wei, Feng
Cao, Shui
Zhang, Xinwei
Dong, Nan
Li, Hui
Ren, Xiubao
CLINICAL COLORECTAL CANCER, 2016, 15 (03) : 228 - 235
[10] THE SURVIVAL BENEFIT OF PRIOR DEFINITIVE LOCAL THERAPY IN MEN WITH ADVANCED/METASTATIC PROSTATE CANCER: RESULTS FROM A PHASE III PROSPECTIVE RANDOMIZED TRIAL.
Williams, Michael
Millikan, Randall
Wang, Xuemei
Pettaway, Curtis
JOURNAL OF UROLOGY, 2010, 183 (04): : E259 - E259

← 1 2 3 4 5 →